Fortive (FTV) Stock Forecast & Price Target

Fortive is well positioned by the accelerating strength of Intelligent Operating Solutions, where 3Q26 core growth reached 9.1% on 7.0% volume growth, broad-based gains across Fluke, FAL, and gas detection, and a book-to-bill above 1x that points to durable demand rather than one-off pricing. The company also posted a 7.2% organic sales increase, adjusted EPS of $0.77 versus $0.70 consensus, and margin expansion to 28.5%, while free cash flow conversion remained strong at about 121%, underscoring earnings quality and cash generation. Although Advanced Healthcare Solutions was softer at 3.1% core growth with some margin pressure, Fortive’s raised full-year guidance to $3.10-$3.14 and continued buybacks, including about $2.3 billion since the July 2025 spin, reinforce confidence in compounding value.

Fortive is viewed negatively because its shares trade above the midpoint of its pre-spin historical relative P/E range while still commanding about a 2% premium on EV/EBITDA versus large-cap Multi-Industry peers, despite weaker organic revenue growth, earnings growth, and ROIC than those peers. The company’s 3–4% core growth target announced in June 2025 looks underwhelming, and its reliance on cyclical industrial and healthcare end markets leaves it exposed to macro slowdowns, government budget cuts, and cyclical healthcare spending. Investor skepticism is further heightened by mixed large-deal execution, uncertainty around expanding recurring/software revenue, and the risk that failure to hit 2026-2027 targets could drive multiple compression from 19.4x 2027E P/E and 15.5x 2027E EBITDA.